Literature DB >> 11832327

EGF receptor downregulation depends on a trafficking motif in the distal tyrosine kinase domain.

Stacie M Jones1, Susan K Foreman, Brian B Shank, Richard C Kurten.   

Abstract

On binding to its receptor, epidermal growth factor (EGF) initiates a cascade of events leading to cell proliferation or differentiation. In addition, the EGF receptor itself is downregulated to attenuate mitogenic signaling. Downregulation occurs through trafficking of receptors to lysosomes, culminating in proteolytic destruction of both the receptor and ligand; however, endocytic sorting mechanisms that underlie lysosomal targeting remain obscure. The goal of this study was to explore one aspect of the molecular basis for ligand-induced lysosomal targeting and degradation of EGF receptors. In this study, we identify a tyrosine-leucine motif ((954)YLVI) that is essential for transit of ligand-receptor complexes to lysosomes. When this motif is mutated, HEK 293 cells expressing the mutant receptors demonstrate impaired lysosomal targeting and downregulation compared with wild-type receptors. (954)YLVI is highly conserved among EGF receptors from various mammalian and invertebrate species and is critical for receptor downregulation. We propose that (954)YLVI works in concert with at least two additional regions within the EGF receptor cytoplasmic domain that are essential for efficiently targeting ligand-receptor complexes to the lysosome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832327     DOI: 10.1152/ajpcell.00253.2001

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  9 in total

1.  Dominant-negative receptor uncovers redundancy in the Arabidopsis ERECTA Leucine-rich repeat receptor-like kinase signaling pathway that regulates organ shape.

Authors:  Elena D Shpak; Michael B Lakeman; Keiko U Torii
Journal:  Plant Cell       Date:  2003-05       Impact factor: 11.277

2.  The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface.

Authors:  Cheri S Lazar; Catherine M Cresson; Douglas A Lauffenburger; Gordon N Gill
Journal:  Mol Biol Cell       Date:  2004-10-06       Impact factor: 4.138

3.  The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells.

Authors:  Mengqian Chen; Li-Mei Chen; Chen-Yong Lin; Karl X Chai
Journal:  Biochim Biophys Acta       Date:  2007-11-12

4.  Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

Authors:  Xiu-Rong Ren; Junping Wei; Gangjun Lei; Jiangbo Wang; Jiuyi Lu; Wenle Xia; Neil Spector; Larry S Barak; Timothy M Clay; Takuya Osada; Erika Hamilton; Kimberly Blackwell; Amy C Hobeika; Michael A Morse; H Kim Lyerly; Wei Chen
Journal:  Breast Cancer Res       Date:  2012-06-07       Impact factor: 6.466

5.  GnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells.

Authors:  Jigal Haas; Libby Ophir; Eran Barzilay; Gil M Yerushalmi; Yuval Yung; Alon Kedem; Ettie Maman; Ariel Hourvitz
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 6.  Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates.

Authors:  Michael Ritchie; Lioudmila Tchistiakova; Nathan Scott
Journal:  MAbs       Date:  2012-12-06       Impact factor: 5.857

7.  Enhanced beta2-adrenergic receptor (beta2AR) signaling by adeno-associated viral (AAV)-mediated gene transfer.

Authors:  Stacie M Jones; F Charles Hiller; Sandie E Jacobi; Susan K Foreman; Laura M Pittman; Lawrence E Cornett
Journal:  BMC Pharmacol       Date:  2003-12-04

8.  Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals.

Authors:  Inna Vainshtein; Lorin K Roskos; Jackie Cheng; Matthew A Sleeman; Bing Wang; Meina Liang
Journal:  Pharm Res       Date:  2014-09-11       Impact factor: 4.200

9.  Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.

Authors:  Tan-Min Chin; Gandhi T K Boopathy; Ellen P S Man; John G Clohessy; Eva Csizmadia; Margaret P Quinlan; Thomas Putti; Seow-Ching Wan; Chen Xie; Azhar Ali; Fhu Chee Wai; Yan Shan Ong; Boon-Cher Goh; Jeff Settleman; Wanjin Hong; Elena Levantini; Daniel G Tenen
Journal:  Theranostics       Date:  2020-02-03       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.